Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Coalition for a Competitive Pharmaceutical Market
Broad Stakeholder Coalition Concludes that the 'Pathway for Biosimilars Act' Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
April 5th, 2008
The Coalition for a Competitive Pharmaceutical Market (CCPM) -- the organization representing a broad range of pharmaceutical stakeholders, including large national employers, insurers, pharmacies and generic drug manufacturers -- strongly urges Congress to develop legislation that will provide safe, effective and affordable biogenerics to consumers. This legislation must provide an appropriate balance between innovation and access to affordable biogenerics through competition. The Pathway for Biosimilars Act will not bring timely patient access to safe and affordable biogeneric medicines as it fails to provide for a workable approval pathway or promote much needed...
Source: Law & Health Weekly (2008-04-05)
|
